Global Diabetes Devices Market to 2033: Relatively Less Stringent Regulatory Policies Drive Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Diabetes Devices Market By Type (BGM Devices, Self-Monitoring Devices, Continuous Glucose Monitoring Devices), By Distribution Channel, By End User, and by Region – Global Forecast to 2023-2033” report has been added to ResearchAndMarkets.com’s offering.

The diabetes devices market size is estimated to be USD 28.45 billion in 2022 and is expected to witness a CAGR of 8.02% during the forecast period 2023-2033.

Companies Mentioned

F. Hoffmann-La-Ltd.

Medtronic plc

Lifescan Inc.

Novo Nordisk

Abbott Laboratories

B Braun Melsungen AG

Lifescan Inc.

Insulet Corporation

Ypsomed Holdings

Dexcom Inc.

Sanofi

Companion Medical

Valeritas Holding Inc.

Arkray Inc.

Growing incidence of diabetes due to aging, obesity, & unhealthy lifestyle, large geriatric population, affordable healthcare facilities, and relatively less stringent regulatory policies are some of the factors contributing to the market growth.

Furthermore, increase in prevalence of new technologically advanced blood glucose monitoring systems, cost-efficient labor, rise in the incidences of obesity, and increasing adoption of insulin delivery devices are other factors supporting the market growth. However, diabetes care devices tend to be quite expensive and challenging to use expected to hinder the growth.

Growing incidence of diabetes due to aging, obesity, & unhealthy lifestyle is expected to fuel the market growth during the forecast period. For instance, in 2021, the International Diabetes Federation (IDF) estimates that 537 million adults worldwide between the ages of 20 and 79 will have diabetes.

Increase in prevalence of new technologically advanced blood glucose monitoring systems is expected to propel the market growth during the forecast period. For instance, in March 2021, the new Accu-Check Instant system, which features Bluetooth connectivity to the mySugr app and transmits blood glucose data to the mySugr app was introduced by Roche. This method helps the business’s patient-centered treatment approach to provide customised diabetes care.

Market Segmentation:

By Type (Revenue, USD Million), 2022 – 2033

BGM Devices

Self-Monitoring Devices

Lancets

Testing Strips

Blood Glucose Meters

Continuous Glucose Monitoring Devices

Receiver

Sensors

Transmitters

Insulin Delivery Devices

Pens

Syringes

Pumps

Jet Injectors

By Distribution Channel (Revenue, USD Million), 2022 – 2033

Retail Pharmacies

Hospital pharmacies

Online Pharmacies

Diabetes Clinics/Centers

By End User (Revenue, USD Million), 2022 – 2033

Homecare

Diagnostic Centers

Hospitals

By Region (Revenue, USD Million), 2022 – 2033

North America

U.S.

Canada

Europe

Germany

France

UK

Spain

Italy

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of APAC

Latin America

Brazil

Mexico

Argentina

Rest of LATAM

Middle East & Africa

South Africa

GCC

Rest of MEA

For more information about this report visit https://www.researchandmarkets.com/r/i0pjm7

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.